Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

232.65 2.70 −1.15%
Market cap
$34.8B
P/E
41.0×
Fwd P/E
31.5×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

9.31% 7.39% 7.70% 4.58%
Piotroski F-Score
5 4 4 3
ROA
5.59% 4.50% 4.77% 2.76%
ROIC
6.71% 5.61% 5.69% 3.11%
Return on Tangible Assets
18.44% 14.89% 14.90% 13.08%
Average Days of Receivables
49.83 49.54 50.29 68.63
Free Cash Flow per Share
15.43 13.78 16.31 17.20
Free Cash Flow
2,262.10 2,019.20 2,401.30 2,540.00
Capital Expenditures
(191.50) (185.40) (189.50) (338.80)
Other line items
Cash ROIC
7.95% 7.12% 8.22% 9.26%
Accounts Receivable Turnover
6.92 7.20 5.91 5.71
Accounts Payable Turnover
5.96 5.62 6.50 6.42
Inventory Turnover
1.07 1.04 1.15 1.12
Average Days of Payables
60.50 65.59 53.72 56.53
Days of Inventory on Hand
323.58 329.16 292.04 333.72
Tax Rate
(0.16) (0.17) (0.15) (0.17)
Research and Development Expense of Revenue
17.71% 17.98% 18.95% 20.08%
Selling, General and Administrative Expense of Revenue
24.15% 24.61% 24.84% 25.87%
Share Based Compensation of Revenue
3.04% 2.94% 2.96% 2.95%
Operating CF/Net income
1.53 1.71 1.89 3.45
Depreciation/Fixed assets
0.31 0.35 0.38 0.45
Capex/Depreciation
(0.20) (0.17) (0.16) (0.25)
Revenue per Share
68.66 67.51 67.51 67.89
Operating CF per Share
16.74 15.05 17.60 19.49
Capex per Share
(1.31) (1.27) (1.29) (2.29)
Capex to Sales
0.02 0.02 0.02 0.03

Fold the line items

Columns are period end dates